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[ ]An  interaction between 14-3-3 and ExoS of P. aeruginosa is 
necessary for ExoS cytoxicity and enzymatic activity 
L. Yasmin, M.S. Francis, B. Hallberg. Dept ofMed. Biosciences/Pathology, Umed 
University, Sweden 
Aim; To investigate the importance of each amino acid of ExoS at the site of 
interaction between ExoS and 14 3-3 and analyze the cytotoxicity and enzymatic 
activity of various ExoS mutants in cell. 
1~ aeruginosa is an opportunistic pathogen. Using type III secretion system, 
1~ aeruginosa secrets 4 toxins, Exoenzyme (Exo) T, U, Y and S, which are 
translocated into the eukaryotic ell. Our research focus on ExoS, which contains 
an N-terminal GAP domain, disrupt actin microfilament structure in cells and 
the C-terminal ADP-ribosylating (ADP-R) domain, which is lethal by blocking 
receptor-stimulated RAS activation in cells. In addition, a eukaryotic Factor Acti- 
vating ExoS or FAS (member of the 14 3-3 protein) is required for the ADP-R 
activity of ExoS and the interaction between 14 3-3 and ExoS is critical for lethality 
and RAS ADP-ribosylation by ExoS. 
Methods: Site directed mutagenesis of ExoS. Infections of cells with bacteria 
harboring different ExoS mutants, followed by resulting activities assay in cells. 
Results; 14 3-3 interacts with ExoS in an unphosphorylated manner which occurs 
in the most C-terminal part of ExoS. ExoS lacking the 14 3-3 binding site has a 
reduced capacity for both to ADP ribosylate RAS and to change the morphology 
of infected cell. Moreover, we are in process to investigate the critical single amino 
acid important for cytotoxicity and the interaction between 14 3-3 and ExoS. 
Conclusion: 14 3-3 is only expressed in eukaryotic ells. It has been suggested 
that the prokaryotic evolution has created away to take advantage of 14 3-3, using 
them as necessary cofactor to activate bacterial toxins. It is apparent that more 
secrets concerning this intriguingly unphosphorylation dependent interaction eeds 
to be uncovered, which will be discussed. 
4. Microbiology 
Fighting Pseudomonas aeruginosa by exploiting its 
communication - quorum sensing 
T. Bjarnsholt 1 , RO. Jensen 2, T.B. Rasmussen 1 , L. Christophersen 2, H. Calum 2, 
H.R Hougen 3, J. Rygaard 3, C. Moser 2, N. Hoiby 2, M. Givskov 1. 1BioCentrum- 
DTU, 2 Rigshospitalet, 3 University of Copenhagen, Denmark 
Conventional ntibiotics have afforded a remarkable increase in the life expectancy 
of cystic fibrosis patients. However, antibiotics target he growth and the basal 
life processes of bacteria, leading to growth arrest and cell death. This selective 
force eventually creates antibiotic resistant bacteria. The most obvious alternative 
to antibiotic-mediated killing would be to attenuate the bacteria with respect o 
pathogenicity. We have previously demonstrated that the cell-cell communication, 
Quorum Sensing (QS) renders P aeruginosa highly tolerant o otherwise lethal 
doses of antibiotics and the bactericidal activity of polymorphonuclear leukocytes 
(PMNs). 
Using a pulmonary mouse model we investigated the impact of blocking the QS 
systems o fP  aeruginosa in vivo, either by genetically mutating the bacteria or QS 
inhibitory (QSI) drugs. The attenuation of QS initially provoked a higher degree of 
inflammation; however the health status and survival of the mice were significantly 
higher. We detected a larger amount of PMNs in BAL fluids, an increased 
endobronchial influx of PMNs, though the production of the PMN chemoattractant 
MIP-2 decreased, as a result of QS blockage. Consequently, blockage of QS led 
to significantly faster clearing of the bacteria nd reduced mortality of the mice. 
These results indicate that/~ aeruginosa, by means of a QS controlled mechanism, 
modulate the early immune response. We hypothesize that the administration of
QSIs, antibiotics and adequate amounts of PMNs, might very well result in only 
the destruction of the bacteria, and no further lung damage. 
Pseudomonas aeruginosa cupA encoded fimbria expression is 
regulated by a GGDEF and EAL domain dependent modulation of 
the intracellular level of cyclic diguanylate 
A. Meissner 1 , V Wild 1 , R. Simm 2, M. Rohde 3, F. Bredenbruch 1 , M. Morr 1 , 
U. R6mling 2, S. H~iussler 1 . 1Division of Cell Biology and Immunology, 
Gesellschafl ~r  Biotechnologische Forschung (GBF), Mascheroder Weg 1, 39124 
Braunschweig, Germany; 2Microbiology and Tumor Biology Center (MTC), 
Karolinska Instituter, Box 280, SE-171 77 Stockholm, Sweden; 3Department of 
Microbiology, Gesellschafl ~r  Biotechnologische Forschung (GBF), Mascheroder 
Weg 1, 39124 Braunschweig, Germany 
Cyclic-diguanylate (c-di-GMP) is a widespread bacterial signal molecule that has 
been implicated to play a role in the modulation of cellular surface components, such 
as exopolysaccharides and fimbria, and in the establishment of a sessile life style. 
We report here on the positive influence of c-di-GMP on cupA encoded fimbria 
expression in Pseudomonas aeruginosa. CupA is induced by either providing 
exogenous c-di-GMP or by overexpression f PAl 120, which contains a GGDEF 
domain. In contrast, overexpression of the EAL domain containing phenotypic 
variance regulator (PvrR) resulted in a decreased intracellular level of c-di-GMR 
in a reduced cupA encoded fimbria expression and as described previously 
in a switch from an auto-aggregative SCV to a non-auto-aggregative wild-type 
phenotype. Thus, both protein domains, the GGDEF and the EAL domain, are 
involved in c-di-GMP turnover in P aeruginosa in vivo and control CupA expression 
and thus biofilm formation. The elucidation of this regulation will significantly 
increase our understanding of bacterial adaptation and might be the basis to initiate 
the development of new antimicrobial treatment s rategies. 
l • T h e  development of an octavalent conjugate P. aeruginosa (Pa) 
vaccine for Cystic Fibrosis (CF) patients: Results from two Phase II 
studies 
D. Bosse 1 , S. Conway 2, E. Mallet 3, M. Ulrich 1 , A.B. Lang 1 , S. Quattrucci 4.
1Berna Biotech Ltd., Berne, Switzerlan& 2 Cystic Fibrosis' Unit, Seacrofi Hospital, 
Leeds', UK; 3H@ital Charles' Nicolle, Rouen, France; 4Istituto di Clinica 
Pediatrica, Ospedale Umberto L Rome, Italy 
Aims; To demonstrate safety and immunogenicity of the octavalent conjugate Pa 
vaccine in CF patients. 
Methods; During 2003 through 2005, 63 CF patients, between 18 months and 18 
years of age (study 01), and 23 infants with CF between the age of 6 and 18 months 
at time of inclusion (study 02) were enrolled in two open, uncontrolled clinical 
trials. All patients were immunized twice (days 1 and 60, "primary immunization"). 
Serum samples were taken at days 1, 60 and 180. Humoral immune responses 
against he 8 serotypes were tested by ELISA. High affinity antibodies having an 
aK > 1 × 106 mol/L for IgG antibodies against Pa IATS-6 LPS were determined. 
Results: There were no deaths during the studies and no withdrawals due to AEs. 
There were a total of 7 SAEs in 01 and 1 SAE in 02, all of which were considered 
unrelated to study medication and resolved without sequelae. Solicited injection 
site reactions occurred in 48%/22% of patients in studies 01/02; while solicited 
systemic reactions were observed in 3%/52% of patients, respectively. In study 02, 
there were statistically significant increases over baseline in IgG for every serotype 
in the vaccine both at day 60 (p 0.0003) and at day 180 (p 0.0004). At days 
60 and 180, 87% and 91% of patients had high affinity antibodies, respectively. 
Results for study 01 are similar. 
Conclusions; For the first time, immunogenicity and induction of high affinity 
antibodies after vaccination of infants with the Pa vaccine has been demonstrated. 
The octavalent Pa vaccine is safe and immunogenic n the studies presented. 
